drugset / Trial / NCT06056752
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, single-center, interventional, dose-escalation clinical study designed to evaluate the safety and tolerability of QH103 Cell Injection in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Timeline
- Start
- 2023-09-27
- Primary completion
- 2025-07-03
- Completion
- 2026-07-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QH103 Cell Injection | Cell therapy | 3e+08 cells | — |
| Subject | QH103 Cell Injection | Cell therapy | 1e+09 cells | — |
| Subject | QH103 Cell Injection | Cell therapy | 3e+09 cells | — |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |